CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

摘要

The present invention relates to chimeric antigen receptors (CAR), which are recombinant chimeric proteins capable of redirecting immune cell specificity and reactivity to selected membrane antigens, and more particularly, wherein the extracellular ligand binding is CD33 positive. It is a scFV derived from a CD33 monoclonal antibody that confers specific immunity against cells. Engineered immune cells believed to carry these CARs are particularly suitable for treating lymphomas and leukemia.